Robotics Company Raises $32M in Additional Funding

Clarapath, a robotics company aimed at catalyzing change in the way pathology laboratories process human and animal tissues, announced this week it has raised $32 million in additional funding.

The round included The 4100 Group, East Post Road Ventures (Investment Arm of White Plains Hospital), Epiphron Capital, Northwell Ventures, P5 Health Ventures, and participation from other strategic organizations. This brings the total raised by Clarapath to more than $39 million. Clarapath is automating processes around the way tissue is processed onto glass slides via “sectioning,” or cutting a cross-section of the tissue specimen.

The company’s first robotic instrument, called SectionStar, is a fully automated system which revolutionizes the reliability and efficiency of the pathology lab. This standardization in the quality of tissue sections is foundational for molecular mapping of human disease and in the development of new treatment pathways.

“This funding will help further develop SectionStar with the goal of launching in the non-clinical market in the very near future and targeting the large clinical market as our ultimate goal. The current funding will help us continue building our team, as well as supporting a robust sales and service effort for our customers,” said Eric Feinstein, CEO of Clarapath, who was recently named one of the 40 under 40 Rising Stars by The Business Council of Westchester.

Clarapath is headquartered and runs its medical device development in Hawthorne. It also has a CLIA-certified Clinical Research Organization (CRO) that serves clinical and research organizations by processing tissue, performing whole slide imaging, and providing automated image processing based in New York City at the New York Genome Center.